Author Profile

Bayer’s Kerendia Wins First T1D CKD Treatment Nod in 30 Years
The oral drug is expected to reduce the risk of eGFR decline and end-stage kidney disease. read more
Lilly Wins Expanded Approval for Oral SERD for Use in Breast Cancer Combo
This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as a monotherapy. read more
Sling Launches Phase 3 Trial to Treat TED with Oral Drug
Linistinib is the only small molecule in late-stage development for active thyroid eye disease. read more
CPHI Milan Pharma Awards 2026 Finalists Announced
The CPHI Pharma Awards has categories for drug development, digital transformation, supply chain, manufacturing, sustainability, partnerships, and leadership. read more
Definium Psychedelic ODT Scores Another Trial Win
This is the company’s third positive phase 3 readout for its DT120 orally disintegrating tablet. read more
Newly-Approved AstraZeneca Pill Fails Late-Stage Breast Cancer Trial
Etcamah didn't meet the primary endpoint of progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer. read more
Novo Nordisk Rebrands as ‘Novo’ in Corporate Culture Overhaul
The rebrand comes as Novo Nordisk races to close the gap with obesity-drug rival Eli Lilly. read more
Trial Win in Hand, Pharvaris Plans 2027 Filings for HAE Drug
The first prophylactic for all three types of HAE, the drug reduced attack rates by 83%. read more
AstraZeneca Gets FDA Approval for 1st-Line Breast Cancer Treatment Regimen
Etcamah in combination with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus standard-of-care treatment. read more
AstraZeneca Completes $600M Oral Lung Cancer Deal with Dizal
AstraZeneca plans to launch Zegfrovy in the U.S. during the fourth quarter of 2026. read more
Novartis MS Pill Hits Goals in Phase 3 Trials
The BTK inhibitor met its primary and key secondary endpoints, while also demonstrating a favorable safety profile. read more
Gilead Gets FDA Approval for Once-Daily Single Tablet for HIV
Bixlenvo is a once-daily single tablet HIV treatment for virologically-suppressed adults. read more
ViiV Gets Green Light for Treatment for Infants Living with HIV
Available in tablets for oral use and oral suspension, Tivicay PD is the first of its kind available to pediatric patients. read more
Hovione Completes $46M+ Expansion of Portugal Tablet Manufacturing Center
The expansion creates commercial-scale batch tablet capacity by bringing spray drying and tableting to the same site. read more
FDA Approves RevMed Pancreatic Cancer RAS Inhibitor
The once daily tablets reduced the risk of death by 60% compared to chemotherapy. read more
Takeda Gets Japan Approval for Novel Narcolepsy Drug
Just weeks after getting the FDA green light, Japan’s Ministry of Health, Labor and Welfare has approved Takeda’s Ozeful tablets. read more
Lilly Launches Oral Weight Loss Drug in the UK
The drug is currently only available through private healthcare and not via the publicly-funded NHS. read more
Teva Gets Priority Review for First-in-Class Oral Tourette’s Therapy
If approved, the drug will be the first new treatment for pediatric patients with Tourette syndrome in 10 years. read more
Trump Nominates Dr. Heidi Overton to Lead FDA
If confirmed by the Senate, the White House domestic policy aide would replace former FDA chief Marty Makary. read more
BioMarin to Buy Alesta to Gain Potential First Oral Therapy for Hypophosphatasia
The first of its kind for hypophosphastasia, the orally-active drug is currently undergoing a phase 1/2a trial. read more

May/June 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Tablets & Capsules

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!